Imaging Brain Tumors With FACBC and Methionine

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 13, 2003

Primary Completion Date

November 27, 2019

Study Completion Date

November 27, 2019

Conditions
Brain CancerCNS Cancer
Interventions
DRUG

FACBC, Methionine

F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.

OTHER

PET Scan

GE Advance PET scanner for sequential body imaging

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00597246 - Imaging Brain Tumors With FACBC and Methionine | Biotech Hunter | Biotech Hunter